Table 1 Studies utilizing SRI to report detailed HRQL for HMV patients

Windisch et al. [13]

Studies reporting change in HRQL

HRQL improvement during HMV

85 stable NIV patients

49 ± 15 (baseline)

61 ± 15 (1 month)

61 ± 16 (1 year)

Struik et al. [23]

NIV vs. standard treatment

108 COPD patients after acute exacerbation

47.9 ± 15.1 (baseline)

55.0 ± 15.4 (12 months)

Murphy et al. [24]

O2 therapy vs NIV + O2 therapy

64 hypercapnic patients after acute exacerbation

50.6 (6 weeks)

Howard et al. [25]

CPAP vs Bi-level PAP

57 OHS patients (outpatient or hospital referral)

50.63 ± 3.65 (baseline)

63.5 ± 3.74 (3 months)

Storre et al. [26]

AVAPS in OHS

10 OHS patients starting NIV

63 ± 15 (baseline)

78 ± 14 (6 weeks BPV-S/T)

76 ± 16 (6 weeks BPV-S/T-AVAPS)

Murphy [27]

Studies reporting HRQL for a specific HMV patient group

High intensity vs high pressure NIV

7 COPD with established HMV

57 ± 11 vs 69 ± 16

Storre et al. [28]

High intensity vs target volume NIV

10 COPD patients with established HMV

59.3 ± 14.8 vs 62.4 ± 18.9

Arellano-Maric et al. [29]

NIV vs CPAP

42 OHS patients with established NIV

61.2 ± 16 vs 65.3 ± 14

Windisch [30]

SRI validation in COPD

162 COPD patients with established NIV

52 ± 17

Walterspracher [31]

SRI for LOT COPD patients

42 COPD patients with established NIV

53.2 ± 18.6

Oga et al. [11]

HRQL tool comparisons

56 COPD/TB patients with established NIV

56.0 ± 15.3

Chen et al. [18]

Chinese SRI validation

149 stable NIV patients

52.93 ± 15.11

Budweiser [8]

Studies reporting HRQL for mixed HMV patient group

Prognostic value of HRQL

231 stable IV and IV patients

61.2 ± 17.7 (all patients)

52.2 ± 15.6 (COPD)

66.2 ± 17.2 (RCWD)

55.3 ± 9.2 (NMD)

71.3 ± 15.7 (OHS/OL)

Gosh et al. [16]

English SRI validation

152 stable NIV and IV patients

55.9 ± 18.9 (all patients)

43.1 ± 17.3 (COPD)

61.9 ± 16.1 (RCWD)

58.8 ± 20.3 (NMD)

53.4 ± 18.8 (OHS)

53.5 ± 19.7 (miscellaneous)

Oga et al. [19]

Japanese SRI validation

56 stable NIV patients

56.0 ± 15.3 (all patients)

56.6 ± 14.7 (COPD)

55.5 ± 16.4 (Tb)

Ribeiro et al. [20]

Portuguese SRI validation

93 stable NIV and IV patients

56.6 ± 15.7 (all patients)

57.0 ± 16.5 (COPD)

55.6 ± 15.1 (OHS)

62.0 ± 12.6 (RCWD)

50.2 ± 16.2 (COPD+OSA)

59.4 ± 19.2 (NMD)

46.0 ± 13.3 (miscellaneous)

Markussen et al. [17]

Norwegian SRI validation

127 stable NIV and IV patients

55.8 ± 18.4 (all patients)

61.0 ± 14.7 (NMD)

43.2 ± 19.0 (COPD)

58.4 ± 18.3 (OHS)

55.8 ± 18.4 (RCWD)

Valko et al. [21]

Hungarian SRI validation

104 stable NIV and IV patients

66.8 ± 15.1 (NIV)

58.2 ± 13.6 (IV)

Huttmann et al. [32]

HRQL after unsuccessful weaning

25 IV patients

49 ± 16 (NMD)

47 ± 20 (COPD)

Huttmann et al. [14]

HRQL of invasively ventilated HMV patients

32 IV patients

53 ± 16 (all patients)

58 ± 16 (NMD)

48 ± 15 (lung diseases)

Raveling et al. [33]

Hypercapnia improvement as a survival predictor

240 COPD patients starting NIV

49.9 ± 15.0 (all patients)

54.6 ± 14.3 (stable patients)

47.9 ± 14.9 (patients after ARF)